Ro vs Sesame Care
Two GLP-1 desks, one scoreboard. We put Ro and Sesame Care head-to-head on the published Brief Score — the same six factors, scored the same way, no pay-to-win placement.
The verdict
Too close to call on the Brief Score.
Ro and Sesame Care are level at 87/100. The scores won't separate them, so the pick comes down to fit: Ro for readers who want a big, brand-name-capable platform and insurance navigation over a published flat price. Sesame Care for shoppers who want genuine fda-approved brand-name glp-1s and the ability to pick their own provider and see the price up front, rather than one fixed compounded program.
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Brief Score.
Factor by factor
Both desks scored on the six published Brief Score factors. The higher score in each row is marked. See the methodology.
Price, coverage & the tracker
| Ro | Sesame Care | |
|---|---|---|
| Brief Score | 87/100 (B+) | 87/100 (B+) |
| Semaglutide | Not disclosed | From $149/mo (brand Wegovy pill) |
| Tirzepatide | Not disclosed | Brand Zepbound (price varies) |
| Coverage | Multi-state | Nationwide marketplace |
| Brand-name access | Yes | Yes |
| Oral / sublingual | Yes | Yes |
| On the tracker | Stableprice stable | Stableprice stable |
Ro: Brand-name access and insurance navigation, but compounded pricing stays off the record.
Sesame Care: Marketplace pricing is set per provider rather than one desk rate; the brand-name Wegovy pill line held its ~$149 entry this cycle.
● Not sold on either?
CoreAge Rx tops the whole board at 94/100.
The steadiest desk on the board: one flat, no-step-up price on both molecules, nationwide, and it hasn't moved.
Pricing, states and access reflect each provider's public disclosures at last review; the Brief Score is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.